Ology Bioservices

Ologie Becomes a 100% Employee-Owned Company

Retrieved on: 
Tuesday, November 14, 2023
Marketing, University, Organization, Culture, ESOP, Education, Management, Ology Bioservices

COLUMBUS, Ohio, Nov. 14, 2023 /PRNewswire/ -- Today Ologie, Inc., announced the transfer of all of its stock into an employee stock ownership plan (ESOP), making the company 100 percent employee owned. The company's shareholders and board of directors, including original founder Bev Ryan and partner Bill Faust, approved the transaction on October 31 with the intent of further strengthening its commitment to its employees and client partners, and to advancing education.

Key Points: 
  • "I couldn't be happier or more excited for our people about this next chapter," said Ologie founder and CEO Bev Ryan.
  • The shift to employee ownership will help preserve Ologie's flexibility and sustainability as an independent company.
  • Ologie is a branding and marketing agency with more than 80 employees across the U.S.
  • To learn more about Ologie, visit www.ologie.com

Cellipont Receives Strategic Debt Investment from OrbiMed to Complete State-of-the-Art Commercial Manufacturing Facility

Retrieved on: 
Tuesday, March 21, 2023
Finance, Clinical Trials, Health Technology, Professional Services, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Ology Bioservices, GMP, Business development, Partnership, Senior, OrbiMed, General partnership, IPSC, CDMO, MSC, Patient, Investment, CFO, Growth, Pharmaceutical industry, Management

Cellipont Bioservices (Cellipont), a cell therapy contract development and manufacturing organization (CDMO), announced a strategic debt facility investment from OrbiMed , a healthcare investment firm.

Key Points: 
  • Cellipont Bioservices (Cellipont), a cell therapy contract development and manufacturing organization (CDMO), announced a strategic debt facility investment from OrbiMed , a healthcare investment firm.
  • The investment will be used by Cellipont to fully finance the previously announced state-of-the-art commercial facility for cell therapies and gene-modified cell therapies in The Woodlands, Texas.
  • "We are energized by this partnership with OrbiMed, which helps us to bring this world-class facility to completion in 2023," said Deborah Wild, President and CEO of Cellipont.
  • Matthew Rizzo, General Partner of OrbiMed, commented “OrbiMed is excited to partner with Cellipont for their continued growth.

Biotechnology Innovators Honored in 2022 BioTech Breakthrough Awards Program

Retrieved on: 
Thursday, November 3, 2022
Growth, Solution, Ology Bioservices, Waters Corporation, Program, PTC, Biotechnology, Industry, Leadership, Honeywell, PTC Therapeutics, Biorefinery, Degenerative disease, Sutro Biopharma, Therapy, Food science, Scientist.com (company), Fine chemical, Vaccine, Industrial design, Professional services, Genomics, Immunology

LOS ANGELES, Nov. 3, 2022 /PRNewswire-PRWeb/ -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe, today announced the results of the second annual BioTech Breakthrough Awards program. The winning BioTech Breakthrough selections for 2022 showcase life sciences and biotechnology companies that push ingenuity and exemplify the best in biotech solutions across the globe.

Key Points: 
  • LOS ANGELES, Nov. 3, 2022 /PRNewswire-PRWeb/ -- BioTech Breakthrough , a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe, today announced the results of the second annual BioTech Breakthrough Awards program.
  • The winning BioTech Breakthrough selections for 2022 showcase life sciences and biotechnology companies that push ingenuity and exemplify the best in biotech solutions across the globe.
  • The mission of the annual BioTech Breakthrough Awards program is to conduct the industry's most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry today.
  • The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more.

Cryoport Reports Results for the Second Quarter 2022

Retrieved on: 
Thursday, August 4, 2022
FDA, Reproductive medicine, U.S. Securities and Exchange Commission, Maas, Follicular lymphoma, Investor relations, Industry, Technology, Growth, SEC, Investment, Medicine, Bristol Myers Squibb, Security (finance), Annual report, Animal Health, Ology Bioservices, Marketing, COVID-19, Company, Program, Blas, Novartis, Tisagenlecleucel, BLA, EDT, Solution, Royal commission, European Commission, SEC filing, MAA, Gilead, Pharmaceutical industry, Video game, Renewable energy, Reinsurance, Review, EU

Biopharma/Pharma revenue increased to $51.7 million, up 14% or $6.2 million for the second quarter of 2022 compared to $45.5 million for the second quarter of 2021.

Key Points: 
  • Biopharma/Pharma revenue increased to $51.7 million, up 14% or $6.2 million for the second quarter of 2022 compared to $45.5 million for the second quarter of 2021.
  • Animal Health revenue increased to $9.6 million, up 14% or $1.2 million for the second quarter of 2022 compared to $8.4 million for the second quarter of 2021.
  • Reproductive Medicine revenue increased to $2.9 million, up 24% or $0.6 million for the second quarter of 2022 compared to $2.3 million for the second quarter of 2021.
  • IMPORTANT INFORMATION: A document titled "Cryoport Second Quarter 2022 In Review", providing a reviewofCryoport'srecentfinancialandoperationalperformanceandageneral businessupdate, will be issued at 4:05 p.m. EDT on Thursday, August 4, 2022.

Capri EGM Acquires R&D Build-to-Suit for National Resilience, a Biomanufacturing Company Contracted by the DOD, Harvard, and Moderna

Retrieved on: 
Friday, February 25, 2022
Research, Construction & Property, Transport, REIT, Biotechnology, Pharmaceutical, Health, Logistics, Supply Chain Management, Retail, Science, Income, COVID-19, Investment, Department, University, Defense, Research, MCM, Organization, Ology Bioservices, Sale, U.S. Department of Defense Strategy for Operating in Cyberspace, Acquisition, Bont, Private, Science, Federal, Capri, R, Harvard University, Lab, Takeda, Fine chemical, Resilience, Newmark, Research, Construction & Property, Transport, REIT, Biotechnology, Pharmaceutical, Health, Logistics, Supply Chain Management, Retail, Science

The property is surrounded by a variety of other symbiotic high-tech uses including bioscience and medical product development, pharma compounding, and R&D firms.

Key Points: 
  • The property is surrounded by a variety of other symbiotic high-tech uses including bioscience and medical product development, pharma compounding, and R&D firms.
  • The proximity to the University of Florida, a top 5 ranked public university, provides a pipeline of talent and research opportunities.
  • Capri EGM believes the pandemic has only increased the need for these types of assets and has highlighted their importance.
  • National Resilience is a technology-focused manufacturing company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption.

Blue Water Vaccines Announces the Appointment of Ronald R. Cobb as the Head of Science and Discovery

Retrieved on: 
Wednesday, August 11, 2021
Hospital, OH, Cincinnati Children's Hospital Medical Center, Wake Forest University, AOM, CEO, Patient, St. Jude Children's Research Hospital, Media, Contract, Ology Bioservices, Medical College of Georgia, Immune system, Tobacco Products Scientific Advisory Committee, Norovirus, Vaccine, University, Solution, Inflammation, CCHMC, Streptococcus pneumoniae, Research, Schering-Plough, Epitope, Schering, Discovery, VLP, Infection, Medical college, Drug development, Pharmaceutical industry

CINCINNATI, August 11, 2021 /PRNewswire/ --Blue Water Vaccines, Inc., a biopharmaceutical company, announced today that it has appointed Dr. Ronald R. Cobb as its Head of Science and Discovery.

Key Points: 
  • CINCINNATI, August 11, 2021 /PRNewswire/ --Blue Water Vaccines, Inc., a biopharmaceutical company, announced today that it has appointed Dr. Ronald R. Cobb as its Head of Science and Discovery.
  • "We look forward to him leading Blue Water Vaccines' pipeline initiatives, which focus on treating and preventing pathogen infections."
  • "I am excited to join the growing team at Blue Water Vaccines and to be involved in the critical process of bringing life-saving vaccines to patients globally," noted Dr. Cobb.
  • As the head of Blue Water Vaccines' scientific initiatives, I plan to propel these ongoing programs forward and establish their clinical path."

Resilience Continues Expansion with Acquisition of Biologics Manufacturing Company Ology Bioservices

Retrieved on: 
Monday, April 12, 2021
General Health, Manufacturing, Other Manufacturing, Health, Chemicals, Plastics, Contents, Life sciences, Ology Bioservices, Biopharmaceutical, Psychological resilience, Resilience

b'Resilience (National Resilience, Inc.), a company building the world\xe2\x80\x99s most advanced biopharmaceutical manufacturing ecosystem, announced it has acquired Ology Bioservices, Inc., (Ology Bio) a privately held company that also specializes in biologic drug substance manufacturing from early stage through commercial products.\nOlogy Bio, based in Alachua, Florida, develops and manufactures drugs and biologics for commercial customers as well as the U.S. government, with more than $1.8 billion in government contracts awarded.

Key Points: 
  • b'Resilience (National Resilience, Inc.), a company building the world\xe2\x80\x99s most advanced biopharmaceutical manufacturing ecosystem, announced it has acquired Ology Bioservices, Inc., (Ology Bio) a privately held company that also specializes in biologic drug substance manufacturing from early stage through commercial products.\nOlogy Bio, based in Alachua, Florida, develops and manufactures drugs and biologics for commercial customers as well as the U.S. government, with more than $1.8 billion in government contracts awarded.
  • Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale.
  • Resilience offers the highest quality and regulatory capabilities, and flexible and adaptive facilities to serve partners of all sizes.
  • By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience frees partners to focus on the discoveries that improve patients\xe2\x80\x99 lives.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210412005972/en/\n'

Ology Bioservices Awarded $37 Million by Department of Defense for Advanced Development of Anti-COVID-19 Monoclonal Antibody Cocktail

Retrieved on: 
Monday, November 23, 2020
Health, Defense, Infectious diseases, Pharmaceutical, Contracts, Biotechnology, Life sciences, Pharmaceutical industry, Health sciences, Biotechnology, Biology, Contract manufacturing organization, Biopharmaceutical, Ology Bioservices, Monoclonal antibody, Mab

Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced today that the Department of Defense (DOD) has awarded the company with an agreement valued at $37 million.

Key Points: 
  • Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced today that the Department of Defense (DOD) has awarded the company with an agreement valued at $37 million.
  • This work is supported by the Office of the Assistant Secretary of Defense for Health Affairs with funding from the Defense Health Agency.
  • The scope of this program includes the activities required to rapidly develop, manufacture, and obtain FDA licensure of a monoclonal antibody (mAb) cocktail (ADM03820) that was originally identified in a previous agreement with the DOD.
  • The company has 183,000 square feet of manufacturing, process development and QA/QC space in its state-of-the-art Advanced Development and Manufacturing Facility in Florida.

BioFlorida Recognizes Florida's Contribution to Fight COVID-19

Retrieved on: 
Friday, October 30, 2020
Ology Bioservices

The Spotlight on Innovation session featured three companies that have achieved major milestones: Medtronic , Ology Bioservices, Inc. , and Bravado Pharmaceuticals .

Key Points: 
  • The Spotlight on Innovation session featured three companies that have achieved major milestones: Medtronic , Ology Bioservices, Inc. , and Bravado Pharmaceuticals .
  • BioFlorida also recognized individuals and organizations for their outstanding achievements across five distinct categories, including this year's newest award, the COVID-19 Innovation Award.
  • This year's award recipients include:
    The COVID-19 Innovation Award recognizes a Florida company that has made significant advances in the fight against COVID-19.
  • As a nationally-recognized expert and key leader on BioFlorida advocacy efforts, Moore has developed passionate advocates for the life sciences industry, as well as new members for BioFlorida.

Ology Bioservices Named 2020 Company Of The Year By BioFlorida

Retrieved on: 
Friday, October 30, 2020
Biotechnology, Health, Science, Pharmaceutical, Research, Life sciences, Health sciences, Health, Pharmaceutical industry, Biotechnology, Ology Bioservices, Biopharmaceutical, Contract manufacturing organization, Ology, Monoclonal antibody, Vaccine, Virus

Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced today the company was named the 2020 David J. Gury Company of the Year by BioFlorida.

Key Points: 
  • Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced today the company was named the 2020 David J. Gury Company of the Year by BioFlorida.
  • BioFlorida distributes the award annually to a company that has achieved significant milestones and has contributed to the growth of Floridas life science industry.
  • We are honored to be named the 2020 BioFlorida Company of the Year, said Peter H. Khoury, Ph.D., President and CEO of Ology Bio.
  • We're excited to recognize Ology Bioservices as the BioFlorida Company of the Year and celebrate their growth and efforts towards manufacturing vaccines, monoclonal antibodies, viruses and nucleic acids for the U.S. government and commercial clients," said Nancy K. Bryan, President and CEO of BioFlorida.